Key facts
- It has raised $500.0M; the latest was Early Stage VC ($500.0M) in Jun 2024.
- Notable investors include Jim Breyer, Stephen Pagliuca, Michael Dell, Elisabeth DeLuca, Michael Chambers.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Arena BioWorks
- ·The full record, as it builds
Funding rounds
No funding rounds for Arena BioWorks are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Arena BioWorks
Operator of a biotechnology company intended to uncover mechanisms of disease by engaging in basic biological research. The company focuses on determining the mechanisms of human disease and advancing new technologies to translate these insights into therapeutics through in-house biotech companies, enabling doctors to accelerate the progression from deep mechanistic human biology to biotech-enabled drug development.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2023
- Employees
- 32
- Website
- arenabio.works/
- Ownership
- Privately Held (backing)
Arena BioWorks doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Arena BioWorks shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Arena BioWorks in its N-PORT filings yet. We sweep new filings monthly.